vs
Side-by-side financial comparison of KalVista Pharmaceuticals, Inc. (KALV) and Lucas GC Ltd (LGCL). Click either name above to swap in a different company.
KalVista Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($13.7M vs $7.5M, roughly 1.8× Lucas GC Ltd). Lucas GC Ltd runs the higher net margin — 5.6% vs -361.4%, a 367.0% gap on every dollar of revenue.
KalVista Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel oral serine protease inhibitor therapies. Its core pipeline addresses unmet medical needs for rare and inflammatory diseases including hereditary angioedema and diabetic macular edema, with primary target markets in North America and Europe.
KALV vs LGCL — Head-to-Head
Income Statement — Q2 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.7M | $7.5M |
| Net Profit | $-49.5M | $414.1K |
| Gross Margin | 91.0% | 33.7% |
| Operating Margin | -336.3% | 4.0% |
| Net Margin | -361.4% | 5.6% |
| Revenue YoY | — | — |
| Net Profit YoY | -17.1% | — |
| EPS (diluted) | $-0.92 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $13.7M | — | ||
| Q2 25 | — | $7.5M | ||
| Q3 24 | $0 | — | ||
| Q2 24 | — | $11.5M |
| Q3 25 | $-49.5M | — | ||
| Q2 25 | — | $414.1K | ||
| Q3 24 | $-40.4M | — | ||
| Q2 24 | — | $1.0M |
| Q3 25 | 91.0% | — | ||
| Q2 25 | — | 33.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 33.5% |
| Q3 25 | -336.3% | — | ||
| Q2 25 | — | 4.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 8.8% |
| Q3 25 | -361.4% | — | ||
| Q2 25 | — | 5.6% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 8.9% |
| Q3 25 | $-0.92 | — | ||
| Q2 25 | — | $0.20 | ||
| Q3 24 | $-0.87 | — | ||
| Q2 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $243.5M | $606.9K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $17.0M | $6.3M |
| Total Assets | $339.9M | $8.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $243.5M | — | ||
| Q2 25 | — | $606.9K | ||
| Q3 24 | $31.8M | — | ||
| Q2 24 | — | $978.1K |
| Q3 25 | $17.0M | — | ||
| Q2 25 | — | $6.3M | ||
| Q3 24 | $172.8M | — | ||
| Q2 24 | — | $5.3M |
| Q3 25 | $339.9M | — | ||
| Q2 25 | — | $8.8M | ||
| Q3 24 | $200.2M | — | ||
| Q2 24 | — | $7.8M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KALV
Segment breakdown not available.
LGCL
| Recruitment service | $4.4M | 60% |
| Others | $2.9M | 39% |
